Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-9-22
pubmed:abstractText
1. Interactions between cholecystokinin octapeptide (CCK-8) and CCKA-receptor antagonists derived from benzodiazepines (devazepide) and glutamic acid (lorglumide and loxiglumide) have been examined in an improved bioassay using the guinea-pig, isolated, gall bladder preparation. 2. The presence of CCKB-receptors in the assay was provisionally-ruled out on the basis of the low potency of pentagastrin in the assay. By applying analyses of both agonism and antagonism, pentagastrin was shown to behave as a partial agonist at the CCKA-receptor. 3. Devazepide, lorglumide and loxiglumide behaved as simple competitive antagonists of CCKA-receptors and pKB values of 9.98, 7.59 and 7.07 were estimated, respectively. 4. Application of a combined dose-ratio analysis to the interactions between CCK-8 and combinations of devazepide/lorglumide and devazepide/loxiglumide indicated that these molecules behave as syntopic, competitive, antagonists at the CCKA-receptor. 5. We conclude that the guinea-pig gall bladder assay contains a homogeneous population of CCKA-receptors and offer an explanation for the differences between our results and those obtained recently by Maubach et al. (1991) which were taken as preliminary evidence for CCKA-receptor heterogeneity.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-14338492, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2064383, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2415196, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2432983, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2721567, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2852288, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2866002, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2900037, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-2909725, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-3014519, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-3440035, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-3663268, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-3781112, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-3978322, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-4339016, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-6055253, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-6141562, http://linkedlifedata.com/resource/pubmed/commentcorrection/1504732-6453221
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
106
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
61-6
pubmed:dateRevised
2010-9-7
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
pubmed:affiliation
Department of Analytical Pharmacology, King's College School of Medicine & Dentistry, Rayne Institute, London.
pubmed:publicationType
Journal Article